Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Nivolumab and relatlimab-rmbw |
Trade Name | Opdualag |
Synonyms | BMS-986213 |
Drug Descriptions |
Opdualag (nivolumab and relatlimab-rmbw) is a fixed-dose combination of Relatlimab (BMS-986016) and Opdivo (nivolumab), which may lead to enhanced anti-tumor immune response (PMID: 34986285). Opdualag (nivolumab and relatlimab-rmbw) is FDA approved for use in adult and pediatric patients of 12 years or older with unresectable or metastatic melanoma (FDA.gov). |
DrugClasses | LAG3 Antibody 18 PD-L1/PD-1 antibody 121 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
IO102-IO103 + Nivolumab and relatlimab-rmbw | IO102-IO103 Nivolumab and relatlimab-rmbw | 0 | 1 |
Ipilimumab + Nivolumab and relatlimab-rmbw + Sarilumab | Ipilimumab Nivolumab and relatlimab-rmbw Sarilumab | 0 | 1 |
Nivolumab and relatlimab-rmbw | Nivolumab and relatlimab-rmbw | 0 | 7 |